Counteracting the sympathetic nervous system in essential hypertension

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 5, 2004, Pages 513-519

  Grassi, Guido ^a,b,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Calcium antagonists; Hypertension; Sympathetic nervous system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; ATHEROGENESIS; CLINICAL FEATURE; CLINICAL RESEARCH; CONGESTIVE HEART FAILURE; DATA ANALYSIS; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; SYMPATHETIC NERVE CELL; SYMPATHETIC TONE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 4344707700     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200409000-00006     Document Type: Review

References (38)

1. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62:347-504.
2. Julius S, Pasqual AV, London R. Role of sympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971; 44:413-418.
3. Watson RDS, Hamilton CA, Reid JL, Littler WA. Changes in plasma norepinephrine, blood pressure and heart rate during physical activity in hypertensive man. Hypertension 1979; 1:341-346.
4. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension 1983; 5:86-99.
5. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999; 17:719-734.
6. Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; 16:1979-1987.
7. Esler MD, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens 1989; 11 (Suppl. 1):s75-s89.
8. Yamada Y, Miyajima E, Tochikubo O, et al. Impaired baroreflex changes in muscle sympathetic nerve activity in adolescents who have a family history of essential hypertension. J Hypertens 1988; 6 (Suppl. 4):s526-s528.
9. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension 1988; 14:1277-1283.
10. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens 1993; 11:647-655.
11. Grassi G, Cattaneo BM, Seravalle G, et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31:68-72.
12. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565. This investigation, based on cardiac norepinephrine spillover as well as on microneurography, reports the relevance of sympathetic overactivity in the development and progression of cardiac hypertrophy.
13. Grassi G, Seravalle G, Bertinieri G, et al. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension in the elderly. J Hypertens 2000; 18:587-693.
14. Greenwood JP, Stoker JB, Walker JJ, Mary DA. Sympathetic nerve discharge in normal pregnancy and pregnancy induced hypertension. J Hypertens 1988; 16:617-624.
15. Greenwood JP, Scott EM, Stoker JB, et al. Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans. Circulation 2001; 104:2200-2204
16. Julius S, Majahalme S. The changing face of sympathetic overactivity in hypertension. Ann Med 2000; 32:365-370.
17. Grassi G, Mancia G. Neurogenic hypertension: is the enigma of its origin near the solution? Hypertension 2004; 43:154-155. This review emphasizes the role of sympathetic neural factors in the genesis of neurogenic hypertension.
18. Grassi G. Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rational and options. Curr Hypertens Rep 2003; 5:277-280. This review provides an overview of the non-pharmacological (physical exercise, dietary sodium restriction and body weight reduction) and pharmacological interventions employed in hypertension treatment and their effects on systemic and regional cardiovascular drive.
19. Sen C, Tarazi RC, Khairaillah P, Bumpus M. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974; 35:775-781.
20. Heagerty AN. Structural changes in resistance arteries in hypertension. In: Zanchetti A, Mancia G, editors. Handbook of hypertension, vol. 17. Pathophysiology of hypertension. Amsterdam, Netherlands: Elsevier Science 1997. pp. 426-437.
21. Morgan H, Baker KN. Cardiac hypertrophy, mechanical, neural, and endocrine dependence. Circulation 1991; 83:13-25.
22. Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake and angiotensin neuromodulation. Hypertension 2004; 43:154-155.
23. Egan BM. Insulin resistance and sympathetic nervous system. Curr Hypertens Rep 2003; 5:247-254.
24. Huggert RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108:3097-3101. An elegant study providing evidence for a synergistic effect of diabetes and hypertension on neuroadrenergic function.
25. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 169:156-162.
26. Grassi G, Seravalle G, Quarti Trevano F, et al. Effects of hypertension and obesity on the sympathetic activation in heart failure patients. Hypertension 2003; 42:873-877.
27. Grassi G. Leptin, sympathetic nervous system and baroreflex function. Curr Hypertens Rep 2004; 6:236-240.
28. Grassi G, Seravalle G, Turri C, et al. Short- versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41:558-562. This study compares the acute versus the chronic effects of the administration of two calcium antagonists on sympathetic nerve traffic and baroreflex function in hypertensive patients.
29. Ohbayashi Y, Tsutamoto T, Sakaguchi T, et al. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 2003; 42 (Suppl. 1):S71-S74. A comparative study on the effect of valsartan versus amlodipine on adrenergic function in hypertensive patients.
30. Kitahara Y, Saito F, Akao M, et al. Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate and sympathetic nervous activity in essential hypertensive patients. J Cardiovasc Pharmacol 2004; 43:68-73.
31. Ruzicka M, Coletta E, Florans J, Leenen FH. Effects of low-dose nifedipine GITS on sympathetic activity in young and older hypertensives. J Hypertens 2004; 22:1039-1044. The authors provide evidence on an age-related discrepancy in the effects of calcium antagonists on adrenergic drive in hypertension.
32. Grassi G. Neuroadrenergic effects of calcium channel blockers: a developing concept. J Hypertens 2004; 22:887-888.
33. Lohmeier TE, Irwin ED, Rossing MA, et al. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004; 43:306-311. Employing a sophisticated experimental approach, in this study the authors provide undisputed evidence for a pathogenetic role of baroreceptor and sympathetic mechanisms in hypertension.
34. Grassi G, Seravalle G, Dell'Oro R, et al. Adrenergic and reflex abnormalities in obese-related hypertension. Hypertension 2000; 36:538-542.
35. Grassi G, Facchini A, Quarti Trevano F, et al. Sympathetic overactivity characterizes human obesity independently on the presence of obstructive sleep apnea [Abstract]. J Hypertens 2003; 21 (Suppl. 4):s117-s118.
36. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43:699-706.
37. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21:1761-1769.
38. Klein IHHT, Ligtenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:428-430. A direct demonstration of the sympathoinhibitory effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension complicated by renal failure.